Welcome to our dedicated page for Ensysce Biosciences SEC filings (Ticker: ENSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ensysce Biosciences, Inc. filings document the formal disclosures of a clinical-stage pharmaceutical issuer developing abuse-resistant and overdose-protection opioid technologies. Recent 8-K reports cover financial results, material financing agreements, registered direct and private-placement securities transactions, and amendments or corrections tied to Series B preferred stock, common-stock issuance and warrants.
The company’s regulatory record also includes Nasdaq listing-compliance notices, annual-meeting voting results, incentive-plan amendments, auditor ratification, director elections, board resignations, committee roles and retention-related compensation arrangements. These filings describe Ensysce’s capital structure, governance, public-company compliance obligations and risk-related corporate events while its TAAP™ and MPAR® platforms remain the core operating focus.
Ensysce Biosciences, Inc. proposes the registration and resale of up to 1,300,000 shares of common stock, consisting largely of shares issuable to a manufacturing counterparty and shares issuable under a separate agreement. The prospectus states the Selling Securityholders will receive all proceeds; the company will pay registration costs.
The company reported 15,365,530 shares outstanding as of June 2, 2026 and disclosed recent financing arrangements that include convertible preferred stock and multiple warrant series. The prospectus notes Nasdaq compliance risks, including a May 21, 2026 notice related to a $2.5 million stockholders’ equity requirement and a bid-price noncompliance notice with a compliance deadline of August 24, 2026. The preliminary prospectus is subject to completion.
Ensysce Biosciences Inc. has received a Nasdaq notice that it no longer meets the exchange’s minimum $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026. The company must submit a compliance plan within 45 days, by July 6, 2026.
If Nasdaq accepts the plan, Ensysce could receive up to 180 days from May 21, 2026 to regain compliance. The company plans to submit a plan and explore options, but there is no assurance Nasdaq or a Nasdaq Hearings Panel will ultimately permit continued listing.
Ensysce Biosciences’ Q1 2026 results highlight rising losses and tight liquidity. Federal grant revenue was $960,999, down from $1,319,772, while operating expenses increased to $4,523,229, driven mainly by higher research and development spending. Net loss widened to $3,556,415 versus $1,945,573 a year earlier.
Cash and cash equivalents fell sharply to $745,482 from $4,310,354 at year-end, and total assets dropped to $2,167,803. Stockholders’ equity turned into a deficit of $669,012, with an accumulated deficit of $143,276,414. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital, despite recent preferred stock and warrant financings.
Ensysce Biosciences reported first quarter 2026 results and outlined key pipeline and strategic developments. Federal grant revenue was $960,999, while research and development expenses rose to $3,346,881 and general and administrative expenses were $1,176,348. Net loss attributable to common stockholders widened to $3,556,415, or $(0.52) per share.
Cash and cash equivalents fell to $745,482 as of March 31, 2026, contributing to a stockholders’ equity deficit of $(669,012). Operationally, the company reached 50% of the interim enrollment target in its pivotal PF614-301 Phase 3 pain trial, advanced its PF614-MPAR® overdose-protected opioid program with new clinical data and IRB approval for PF614-MPAR-102 Part 3, and expanded its ADHD and OUD pipelines and patent estate. The board also launched a formal review of strategic alternatives, including potential partnerships and licensing deals.
Ensysce Biosciences, Inc. registers up to 20,335,491 shares of common stock for resale by selling securityholders. The resale pool consists of Conversion Shares issuable on conversion of Series B preferred stock and shares issuable upon exercise of multiple warrant series. The registration covers resale only; the company will not receive proceeds from these resales but will receive proceeds if the Investor Warrants are exercised for cash. The prospectus discloses 9,277,819 shares of common stock outstanding as of April 2, 2026, a reported last sale price of $0.6096 per share on April 2, 2026, a going concern explanatory paragraph in the 2025 audited financials and cash to fund operations into the second quarter of 2026. The filing details conversion-price adjustments, beneficial-ownership limits (4.99%/9.99%), extensive anti-dilution mechanics and resale methods permitted under the Plan of Distribution.
Ensysce Biosciences entered a new financing tranche, closing a private offering of $2 million in Series B preferred stock on April 6, 2026 under a 2025 commitment of up to $20 million over 24 months.
The company issued 2,000 Series B preferred shares convertible into up to 4,363,636 common shares at a fixed price of $0.55 per share, plus Warrants to purchase up to 8,727,273 common shares at the same price, with 18‑month and five‑year terms. Net proceeds of about $1.9 million are earmarked for general corporate purposes and development of its TAAP and MPAR® pain programs.
Ensysce Biosciences Inc. reported that board member Dr. Curtis Rosebraugh resigned from its Board of Directors, effective April 1, 2026. He also stepped down from the Board’s Nominating and Corporate Governance Committee. His written resignation notice is included as Exhibit 17 to the report.
Ensysce Biosciences is a clinical-stage pharmaceutical company developing abuse-resistant and overdose-protective opioid pain therapies using its TAAP and MPAR platforms. Lead drug PF614, an extended-release oxycodone prodrug, has completed multiple Phase 1 trials and human abuse potential studies, and a pivotal Phase 3 post-surgical pain trial began enrollment in December 2025.
Combination candidate PF614-MPAR, which adds nafamostat for overdose protection, has shown reduced oxycodone exposure in simulated overdose settings and received FDA Breakthrough Therapy designation in January 2024. The company highlights substantial ongoing losses, a need for significant additional funding, reliance on PF614 and PF614-MPAR, Nasdaq delisting risk, and extensive regulatory and intellectual property uncertainties.
Ensysce Biosciences reported fourth quarter and full year 2025 results alongside clinical and regulatory progress for its opioid safety pipeline. The company advanced lead pain candidate PF614 into a pivotal Phase 3 post‑surgical pain trial and continued development of PF614‑MPAR, which has FDA Breakthrough Therapy designation for its overdose‑protection technology.
PF614‑301 Phase 3 enrollment is underway, and the FDA provided supportive feedback for PF614‑MPAR, including potential use of a streamlined 505(b)(2) pathway and overdose‑protection labeling. Ensysce also expanded its intellectual property, with a new U.S. patent on MPAR® technology extending protection to 2042 and a European notice of allowance for an amphetamine prodrug patent.
Financially, federal grant funding was $5.1 million in 2025, while research and development expenses rose to $10.4 million and general and administrative costs were $4.9 million. Net loss attributable to common stockholders increased to $10.2 million for 2025, with fourth quarter loss of $2.8 million. Cash and cash equivalents were $4.3 million at December 31, 2025, supported by $8.7 million of net cash provided by financing activities. As a clinical‑stage biotech, the company expects continued losses as it invests in late‑stage trials and pipeline growth.